Leerink Partners Downgrades Alnylam Pharmaceuticals (ALNY) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 227.66 +2.56 (1.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $225.10 | 52 Week High | $109.10 | |||
| Open | $224.92 | 52 Week Low | $31.38 | |||
| Day High | $229.82 | P/E | N/A | |||
| Day Low | $223.76 | EPS | $-1.45 | |||
| Volume | 1,338,223 | |||||
